News | December 05, 2014

Research Uncovers new way to Help Predict Outcomes for TAVR Patients

A retrospective analysis from the Minneapolis Heart Institute Foundation reveals that tricuspid regurgitation (TR) can help doctors predict which patients may have poor outcomes from the TAVR procedure

Clinical Trial, Heart valve repair, TAVR

December 5, 2014 – An estimated quarter of a million of older adults are diagnosed with aortic valve stenosis each year. And the treatment options, which include open-heart surgery to replace the aortic valve and less invasive transcatheter aortic valve replacement (TAVR), come with serious risks as well, including death.

New research from the Minneapolis Heart Institute Foundation has uncovered a way to help interventional cardiologists better predict which patients are at higher risk for death following TAVR, allowing both patient and surgeon to discuss a potentially different treatment plan.

Cardiologists and heart surgeons already look closely at tricuspid regurgitation (TR) in patients who are candidates for surgical aortic valve replacement, because the condition can tell them how likely the patient is to benefit from the procedure. This new research shows that TR may help cardiologists identify patients who are good (or poor) candidates for the minimally invasive TAVR procedure too.

To assess the impact of TR on TAVR outcomes, MHIF researchers analyzed the medical records of 129 TAVR patients. They looked at TR both before the procedure (baseline) and 30 days after, and classified the condition as none, mild, moderate or severe. The cases were divided into two groups according to baseline TR: none (n=89) and significant (anything worse than mild) (n=32). Survival following TAVR was significantly worse both in patients with significant TR and in patients who developed late TR (TR that had worsened to either moderate or severe at 30 days follow-up). The results were independent of baseline left ventricular ejection fraction (LVEF).

“While we don’t know yet whether this is cause and effect or TR is simply a marker for poor heart function,” said co-researcher Robert Schwartz, M.D., FACC, FAHA, “TR status and severity should be included in TAVR risk assessments to guide treatment decisions and aid in prognosis.”

For more information: www.mplsheart.org

Related Content

Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
News | Heart Valve Technology | January 15, 2019
Boston Scientific Corp. and Edwards Lifesciences Corp. announced that the companies have reached an agreement to settle...
The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as a arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital. Dr. Dominick Wiktor. The TEE is from a Philips Epiq system.

The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as an arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital.

Feature | Heart Valve Technology | January 14, 2019 | Allen Atchley, M.D., FACC, The Chattanooga Heart Institute
Mitral regurgitation (MR) is one of the most common types of heart valve diseases in the United States, affecting app
JC Medical Announces First U.S. Treatment With J-Valve TAVR Device
News | Heart Valve Technology | January 07, 2019
January 7, 2019 — JC Medical announced the successful treatment of the first U.S.
Edwards' Sapien 3 Ultra Transcatheter Heart Valve Receives FDA Approval
Technology | Heart Valve Technology | January 02, 2019
Edwards Lifesciences Corp. announced that the Sapien 3 Ultra system has received U.S. Food and Drug Administration (FDA...
Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
Overlay Init